AUROPHARMA / FY26 summary

The year in one view.

Aurobindo Pharma · annual summary assembled from the available FY26 source records.

Research layer active

Revenue across quarters

85,525

₹ Cr where applicable

PAT across quarters

9,232.8

₹ Cr where applicable

Source quarters

11

₹ Cr where applicable

EBITDA (₹ Cr)PositiveWatchNegative
9 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY24: 1,151.4 · Positive source sentiment · 2023-08-14Q1 FY24Q2 FY24: 1,403 · Positive source sentiment · 2023-11-09Q2 FY24Q3 FY24: 1,601 · Positive source sentiment · 2024-02-12Q3 FY24Q4 FY24: 1,687 · Positive source sentiment · 2024-05-27Q4 FY24Q2 FY25: 1,566 · Positive source sentiment · 2024-11-11Q2 FY25Q3 FY25: 1,628 · Positive source sentiment · 2025-02-12Q3 FY25Q4 FY25: 1,792 · Positive source sentiment · 2025-05-15Q4 FY25Q1 FY26: 1,603 · Watch source sentiment · 2025-08-14Q1 FY26Q2 FY26: 1,678 · Positive source sentiment · 2025-11-14Q2 FY261,7921,151.4
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.